Nektar Therapeutics Cash Flow - Annual (NASDAQ:NKTR)

Add to My Stocks
$19.39 $0.53 (2.81%) NKTR stock closing price Apr 25, 2017 (Closing)

The Nektar Therapeutics cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. The profit-loss statement shows Nektar Therapeutics profits, the balance sheet shows Nektar Therapeutics debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. Items like capital purchases, bank loan payments etc. which have a direct impact on the cash position of a company come out through the statemement of cash flows and help an investor who undertakes the Nektar Therapeutics stock analysis. Nektar Therapeutics generated $-117.02M cash from operating activities in 2016. Nektar Therapeutics had an outflow of $43.94M from operating activities, $72.83M inflow due to financing activities, and $68.07M spend due to investing activities for 2016. View details of Nektar Therapeutics cash flows for latest & last ten financial years.

show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec. 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Nektar Therapeutics Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow15.35M12.85M12.92M14.27M14.5M14.95M16.55M14.88M22.48M28.15M
Net Increase (Decrease) in Assets Liabilities7.93M-34.7M-116.42M90.58M1.6M-14.95M-64.65M117.7M-26.79M106.75M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net13.21M29.94M15.4M18.62M25.98M20.24M30.17M9.66M-107.14M44.15M
Nektar Therapeutics Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-6.39M-11.19M-9.97M-4.09M-10.58M-9.72M-31.45M-20.7M-18.85M-32.79M
Acquisition Disposition of Subsidiaires--------4.44M114.83M-
Increase (Decrease) in Investments-76M-28.14M-27.59M54M148.6M-102.23M48.16M-123.89M178.67M0.14M
Other Cash Inflow (Outflow) from Investment Activities-25M---25M-----
Nektar Therapeutics Net Cash from (used by) Invesment Activities
Issuance (Purchase) of Equity Shares209.56M32.2M163.52M8.2M4.11M224.31M8.89M4.82M0.38M3.78M
Issuance (Repayment) of Debt Securities-5.94M98.57M-3.53M-2.99M-96.9M-1.97M-1.35M-1.28M-50.12M-105.54M
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities
Nektar Therapeutics Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash-0.12M-0.15M-0.1M0.03M0.06M0.91M-0.21M-0.22M0.16M0.65M
Nektar Therapeutics Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year55.57M12.36M39.06M25.43M15.31M17.75M49.59M155.58M76.29M63.76M
Cash & Equivalents at Year End59.64M55.57M12.36M39.06M25.43M15.31M17.75M49.59M155.58M76.29M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years
Get Cash flow for another ticker

Nektar Therapeutics stock comparison chart provides an easy way to compare the stock price with peers along with details of Nektar Therapeutics stock price history.
The statement of cash flows can be categorized into three main sections:
  • Nektar Therapeutics has cash of $59.64M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Nektar Therapeutics stock price.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. Nektar Therapeutics lost $43.94M cash from operations. It is important to check this to see where the company is getting its money from.
  • Growth companies (typically most tech companies) spend heavily  on investing activities and this figure was negative at $-82.4M for NKTR stock. Sometimes a company might have a negative overall cash flow which may not be really bad if it is due to investment expenses. Hence it is important to check the cash flow from investment activities.
  • Cash flow from financing activities shows the flow of cash between Nektar Therapeutics and its owners and creditors and was $203.61M for 2016. Financing activities allow a company to raise capital, and repay bondholders.

Key Financial Ratios For Nektar Therapeutics Cash Flow

FCF margin